Marché mondial des tests sanguins maternels – Tendances et prévisions de l’industrie jusqu’en 2030

Analyse et taille du marché des tests sanguins maternels

L’un des principaux facteurs à l’origine de la croissance du marché des tests sanguins maternels est l’amélioration continue du scénario de remboursement du NIPT dans le monde. L’augmentation de l’incidence des anomalies chromosomiques, combinée à l’utilisation croissante du produit dans de nouvelles applications, stimule la croissance du marché. La préférence croissante pour les techniques non invasives par rapport aux méthodes invasives, ainsi que l’augmentation des programmes visant à accroître la sensibilisation au NIPT, ont toutes un impact sur le marché.

Français Data Bridge Market Research analyse que le marché des tests sanguins maternels, qui était de 3,807 milliards USD en 2022, devrait atteindre 10,12 milliards USD d'ici 2030, à un TCAC de 13,00 % au cours de la période de prévision 2023 à 2030. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché des tests sanguins maternels  

Définition du marché

A maternal blood test is a type of prenatal screening test that determines the likelihood that a chromosome disorder will impact a pregnancy or certain behavioural issues will impact a pregnancy. The primary goal of the test is to ensure that the baby does not have any chromosomal abnormalities such as Down syndrome. These tests are known to be capable of providing more information about pregnancy health.

Global Maternal Blood Test Market Dynamics

Drivers

• Rising use of maternal blood tests

Maternal blood tests can detect and diagnose chromosomal rearrangements, X-linked diseases, and aid in the reduction of spontaneous abortions, increased implantation rates, the prevention of trisomic offspring, and the avoidance of the risk of transmitting single gene disorders. However, PGS and PGD results are not 100% accurate, and if necessary, diagnostic tests such as amniocentesis and CVS must be performed after pregnancy to confirm the positive PGS/PGD results. In the United States alone, more than 63,000 babies were born through IVF in 2013, an increase of 2,000 births from 2012. These are the certain test that help the market to grow.

Opportunities

• Introduction of NIPTs

The introduction of NIPTs using cell-free foetal DNA (cffDNA) in 2011 was the most significant advancement in the field of prenatal screening. Obstetricians and patients who are put off by ultrasound screening's 10% to 15% false positive rate and maternal serum test's 5% false positive rate are eagerly embracing NIPTs that claim to have only a 5% false positive rate. In just four years, molecular genetics companies have successfully developed eight different types of kits for detecting genetic abnormalities in foetus. These products have gradually marginalized maternal serum tests, and maternal serum tests are expected to become obsolete within the next decade.

Restraints/Challenges

• Lack of skilled professionals

Lack of skilled and trained professionals, strict regulatory guidelines and ethical stumbling blocks limits the market's growth during the forecast period.

This maternal blood test market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the maternal blood test market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Maternal Blood Test Market Scope

The maternal blood test market is segmented on the basis of type, tested condition and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Combined First Trimester Screening
• Second Trimester Maternal Serum Screening

 Tested Conditions

• Edwards Syndrome
• Patau Syndrome
• Down syndrome
• Neural Tube Defects

End-User

• Diagnostic Laboratories
• Hospitals

Maternal Blood Test Market Regional Analysis/Insights

The maternal blood test market is analyzed and market size insights and trends are provided by country, type, tested condition and end-user as referenced above.

The countries covered in the maternal blood test market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the maternal blood test market because of the high adoption of advanced technologies within the region. 

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 owing to the developing healthcare infrastructure, and increasing awareness programs and conferences in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The maternal blood test market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for maternal blood test market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the maternal blood test market. The data is available for historic period 2011-2021.

Competitive Landscape and Maternal Blood Test Market Share Analysis

Le paysage concurrentiel du marché des tests sanguins maternels fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché des tests sanguins maternels.

Certains des principaux acteurs opérant sur le marché des tests sanguins maternels sont :

• CENTOGENE NV (Allemagne)
• SÉQUENCE (États-Unis)
• Natera, Inc. (États-Unis)
• Génétique LifeLabs (Canada)
• Sema4 OpCo, Inc. (États-Unis)
• Invitae Corporation (États-Unis)
• Illumina, Inc. (États-Unis)
• Thermo Fisher Scientific Inc. (États-Unis)
• General Electric (États-Unis)
• PerkinElmer Inc. (États-Unis)
• Agilent Technologies, Inc. (États-Unis)
• BGI (Chine)
• F. Hoffmann-La Roche SA (Suisse)
• YOURGENE HEALTH (Royaume-Uni)
• Eurofins Scientifique (Luxembourg)
• Diagnostic EKF (Allemagne)

SKU-47812